Status:
UNKNOWN
Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.
Eligibility Criteria
Inclusion
- STEMI patients
- chest pain for less than 12hr
- plan to PCI
Exclusion
- LM lesion
- stent thrombosis
- cardiac shock
- thrombocytopenia
- allergy to asprin
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01181388
Start Date
April 1 2010
End Date
October 1 2012
Last Update
August 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the 28th division, Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029